Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Accumulated Depreciation (2016 - 2025)

Celldex Therapeutics has reported Accumulated Depreciation over the past 15 years, most recently at $23.9 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation at $23.9 million for Q4 2025, up 1.88% from a year ago — trailing twelve months through Dec 2025 was $23.9 million (up 1.88% YoY), and the annual figure for FY2025 was $23.9 million, up 1.88%.
  • Accumulated Depreciation for Q4 2025 was $23.9 million at Celldex Therapeutics, up from $23.5 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for CLDX hit a ceiling of $23.9 million in Q4 2025 and a floor of $21.1 million in Q4 2021.
  • Median Accumulated Depreciation over the past 5 years was $22.4 million (2023), compared with a mean of $22.5 million.
  • Biggest five-year swings in Accumulated Depreciation: dropped 0.52% in 2021 and later rose 4.82% in 2024.
  • Celldex Therapeutics' Accumulated Depreciation stood at $21.1 million in 2021, then increased by 2.37% to $21.6 million in 2022, then increased by 3.51% to $22.4 million in 2023, then grew by 4.82% to $23.5 million in 2024, then rose by 1.88% to $23.9 million in 2025.
  • The last three reported values for Accumulated Depreciation were $23.9 million (Q4 2025), $23.5 million (Q4 2024), and $22.4 million (Q4 2023) per Business Quant data.